Press releases
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
- Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
- Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
On Friday, Akeso Inc (4RY:FRA) closed at 5.55, -8.26% below its 52-week high of 6.05, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.80 |
---|---|
High | 5.80 |
Low | 5.55 |
Bid | 5.55 |
Offer | 6.10 |
Previous close | 5.60 |
Average volume | 12.00 |
---|---|
Shares outstanding | 865.86m |
Free float | 634.96m |
P/E (TTM) | 18.75 |
Market cap | 42.43bn HKD |
EPS (TTM) | 2.61 HKD |
Data delayed at least 15 minutes, as of May 03 2024 14:29 BST.
More ▼